Future research should further elucidate the molecular mechanisms underpinning the role of the HGF/c‐Met pathway in renal cancer initiation and progression and explore safer and more effective c‐Met inhibitors, ultimately providing innovative strategies for the precision treatment of renal cancer. This evidence concerns the gene MET and renal carcinoma.